Fig. 3: Induction of partially exhausted phenotype CD8+ T cells with teplizumab in clinical trial participants.
From: Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes
A Frequency of CD8+ Eomesodermin (EOMES)+ T cells among CD8+ central memory (CM) T cells in the EBV-seropositive (n = 16) vs EBV-seronegative (n = 22) teplizumab treated in the TN10 trial by flow cytometry, (A, **p = 0.004). B Frequency of CD8+EOMES+ T cells in the EBV-seropositive (n = 10) vs EBV-seronegative (n = 18) teplizumab treated in the AbATE trial by flow cytometry, (**p = 0.004, *p = 0.01). C Frequency of KLRG1+ TIGIT+ effector memory (EM) CD8+ T cells in the TN10 trial among EBV-seropositive (n = 16) vs EBV-seronegative (n = 22) participants by flow cytometry with teplizumab treatment (****p < 0.0001, *p = 0.02). D Frequency of KLRG1+ TIGIT+ CM CD8+ T cells in the EBV-seropositive (n = 16) vs EBV-seronegative (n = 22) participants by flow cytometry with teplizumab treatment (****p < 0.0001, *p = 0.016). E Frequency of KLRG1+TIGIT+ CD8+ T cells in the AbATE trial (*p = 0.02). A–E, the data are the mean values +/− 95% CI from a mixed model for repeated measures without correction for the baseline or multiple comparisons. Control: EBV-seronegative: square magenta, EBV-seropositive: square green; Teplizumab EBV-seronegative triangle yellow, EBV-seropositive inverted triangle blue. The group comparisons are shown in the legends). Source data are provided in the Source Data file.
